Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome (MYOPK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03059173
Recruitment Status : Not yet recruiting
First Posted : February 23, 2017
Last Update Posted : August 7, 2019
Sponsor:
Collaborator:
Ministry of Health, France
Information provided by (Responsible Party):
University Hospital, Lille

Brief Summary:
The main objective will be to check if MyoInositol (MYO) reduces the total resistance rate to Clomiphene Citrate (CC). For this, our study will be controlled, randomized and double blinded. It will include patients with PCOS (polycystic ovary syndrome, defined by the Rotterdam criteria) who wish to become pregnant and are eligible to simple ovulation induction by CC. Half of them will receive MYO + folic acid (FA) in addition to the CC, while the other half will receive a placebo containing only FA in addition to the CC. The MYO supplementation will be initiated at least one month before taking CC and will be continued throughout this treatment until pregnancy or before switching to another type of treatment for ovulation induction if no pregnancy is obtained after 6 ovulatory cycles.

Condition or disease Intervention/treatment Phase
Polycystic Ovary Syndrome Reproductive Medicine Dietary Supplement: Inofolic (r) Drug: Clomiphene Citrate Dietary Supplement: placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 276 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome During Induction of Ovulation With Clomiphene Citrate
Estimated Study Start Date : November 2019
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2020


Arm Intervention/treatment
Active Comparator: Inositol + Clomiphene Citrate
The experimental group will receive the dietary supplement: 4 g of MYO + 0.4 mg of FA per day per os (in 2 bags per day) in addition to the standard therapy Clomiphene citrate (CC).
Dietary Supplement: Inofolic (r)
Dietary supplement Inofolic containing myo-inositol (4 g) and folic acid (0.2 mg) in a same bags Supplementation started on average one month before treatment with Clomiphene citrate and continued throughout cycles of Clomiphene citrate (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle.
Other Name: myo-inositol + folic acid

Drug: Clomiphene Citrate
Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.

Placebo Comparator: Placebo + Clomiphene Citrate
The control group will receive the standard therapy CC and a placebo containing only 0.4 mg of FA.
Drug: Clomiphene Citrate
Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.

Dietary Supplement: placebo
Placebo Dietary supplement containing placebo substance and folic acid (0.2 mg)in a same bags
Other Name: placebo + folic acid




Primary Outcome Measures :
  1. Total resistance rate under CC for ovulation induction in patients with PCOS. [ Time Frame: At each cycle during 4 months ]
    The total resistance to CC is defined by failure to ovulate at least one time during 4 subsequent cycles in women requiring 150 mg/day from D2 to D6.


Secondary Outcome Measures :
  1. Rate of responders (i.e., 100% cycles with ovulation and/or occurrence of a pregnancy) at doses of 50 and 100mg of CC [ Time Frame: At each cycle during one year ]
  2. Rate of drop out [ Time Frame: at each cycle during one year ]
  3. Cumulative incidence of clinical pregnancy (cardiac activity on ultrasound at 6 weeks of amenorrhea) [ Time Frame: During one year ]
  4. Rate of patients switched to a 2nd line treatment with exogenous gonadotropins over the whole period of the study [ Time Frame: At each cycle during one year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Woman of childbearing age
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Wishing pregnancy,
  • Having PCOS defined by the Rotterdam criteria: high antral follicle count (AFC) (> 19 per ovary) and/or a disorder of the cycle and/or hyperandrogenism (at least two of the three criteria),
  • Having never been treated with CC (or previous treatment with CC interrupted for > 3 months).
  • Having received complete information and having signed consent.
  • Covered by social security

Exclusion Criteria:

  • Intolerance to CC in previous treatment,
  • BMI > 35,
  • Other associated cause of oligoanovulation requiring specific treatment (eg., Hyperprolactinemia or functional hypothalamic anovulation),
  • Ongoing pregnancy at the time of CC initiation,
  • Other male or female cause of hypo-fertility,
  • History of ovarian drilling,
  • Negative rubella serology.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03059173


Contacts
Layout table for location contacts
Contact: Goeffrey ROBIN, MD 320446252 ext +33 goeffrey.robin@chru-lille.fr

Sponsors and Collaborators
University Hospital, Lille
Ministry of Health, France
Investigators
Layout table for investigator information
Principal Investigator: Goeffrey Robin, MD University Hospital, Lille
Layout table for additonal information
Responsible Party: University Hospital, Lille
ClinicalTrials.gov Identifier: NCT03059173    
Other Study ID Numbers: 2015_68
2016-A01246-45 ( Other Identifier: ID-RCB number, ANSM )
PHRC_N_15-0116 ( Other Identifier: PHRC number )
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: August 7, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Lille:
Polycystic ovary syndrome
Reproductive medicine
Additional relevant MeSH terms:
Layout table for MeSH terms
Polycystic Ovary Syndrome
Syndrome
Disease
Pathologic Processes
Ovarian Cysts
Cysts
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Folic Acid
Vitamin B Complex
Inositol
Clomiphene
Enclomiphene
Zuclomiphene
Hematinics
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents